Found: 17
Select item for more details and to access through your institution.
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-00536-8
- By:
- Publication type:
- Article
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. 1, doi. 10.1186/s13045-019-0801-y
- By:
- Publication type:
- Article
Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction.
- Published in:
- Nature Biotechnology, 2017, v. 35, n. 1, p. 35, doi. 10.1038/nbt.3677
- By:
- Publication type:
- Article
Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39986-1
- By:
- Publication type:
- Article
Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy.
- Published in:
- PLoS ONE, 2013, v. 8, n. 1, p. 1, doi. 10.1371/journal.pone.0051805
- By:
- Publication type:
- Article
Development and Characterization of Recombinant Ovine Coagulation Factor VIII.
- Published in:
- PLoS ONE, 2012, v. 7, n. 11, p. 1, doi. 10.1371/journal.pone.0049481
- By:
- Publication type:
- Article
The Immune Response to the fVIII Gene Therapy in Preclinical Models.
- Published in:
- Frontiers in Immunology, 2020, p. 1, doi. 10.3389/fimmu.2020.00494
- By:
- Publication type:
- Article
Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1294555
- By:
- Publication type:
- Article
Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.697602
- By:
- Publication type:
- Article
Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 58, n. 1, p. 117, doi. 10.1007/s00280-005-0156-7
- By:
- Publication type:
- Article
Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2004, v. 53, n. 2, p. 107, doi. 10.1007/s00280-003-0717-6
- By:
- Publication type:
- Article
Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.
- Published in:
- Journal of Gene Medicine, 2010, v. 12, n. 4, p. 333, doi. 10.1002/jgm.1442
- By:
- Publication type:
- Article
Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII.
- Published in:
- Molecular Therapy, 2011, v. 19, n. 2, p. 302, doi. 10.1038/mt.2010.239
- By:
- Publication type:
- Article
Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A.
- Published in:
- Molecular Therapy, 2009, v. 17, n. 7, p. 1145, doi. 10.1038/mt.2009.35
- By:
- Publication type:
- Article
Hematopoietic Stem Cells Encoding Porcine Factor VIII Induce Pro-coagulant Activity in Hemophilia A Mice with Pre-existing Factor VIII Immunity.
- Published in:
- Molecular Therapy, 2007, v. 15, n. 6, p. 1093, doi. 10.1038/sj.mt.6300146
- By:
- Publication type:
- Article
Characterization of a molecular switch system that regulates gene expression in mammalian cells through a small molecule.
- Published in:
- BMC Biotechnology, 2010, v. 10, p. 1, doi. 10.1186/1472-6750-10-15
- By:
- Publication type:
- Article
Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1331322
- By:
- Publication type:
- Article